Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis

New England Journal of Medicine

Volumn 339, Issue 5, 1998, Pages 292-299

  Saag, Kenneth G ^a,k   Emkey, Ronald ^b   Schnitzer, Thomas J ^c   Brown, Jacques P ^d   Hawkins, Federico ^e   Goemaere, Stefan ^f   Thamsborg, Gorm ^g   Liberman, Uri A ^h   Delmas, Pierre D ⁱ   Malice, Marie Pierre ^j   Czachur, Michelle ^j   Daifotis, Anastasia G ^j   Lane, Nancy ^l   Correa Rotter, Ricardo ^m   Yanover, Melissa ⁿ   Westhovens, Rene ^o   Epstein, Sol ^p   Adachi, Jonathan D ^q   Poubelle, Patrice ^d   Melo Gomes, Jose ^r   Rodriguez Portales, Jose A ^s   more..

^a UNIVERSITY OF IOWA   (United States)

^b Bone Research Center   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d LAVAL UNIVERSITY   (Canada)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g Osteoporose centret Kommunchopitalet ^*  (Denmark)

^h Beilison Medical Center   (Israel)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j MERCK RESEARCH LABORATORIES   (United States)

^k UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

ⁿ W Nephrology and Metab Bone Dis   (United States)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p ALBERT EINSTEIN MEDICAL CENTER   (United States)

^q ST JOSEPH S HOSPITAL   (Canada)

^r Hospital Militar Principal   (Portugal)

^s PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; PLACEBO; VITAMIN D;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADOLESCENT; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREDNISONE; RISK FACTORS; SPINAL FRACTURES;

EID: 18244431006     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199807303390502     Document Type: Article

References (33)

1. Saag KG. Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. Am J Med 1997;103:Suppl 6A:31S-39S.
2. Dequeker J, Westhovens R. Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: bones of contention. J Rheumatol 1995;22:1013-9.
3. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
4. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991;18:804-8.
5. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
6. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37:1499-505.
7. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest 1979;64:655-65.
8. Verstraeten A, Dequeker J, Nijs J, Geusens P. Prevention of postmenopausal bone loss in rheumatoid arthritis patients: a two-year prospective study. Clin Exp Rheumatol 1989;7:351-8.
9. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
10. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-8.
11. Dykman TR, Haralson KM, Gluck OS, et al. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984;27:1336-43.
12. Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80.
13. Adachi JD, Bensen WG, Blanchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996;23:995-1000.
14. Fleisch H. New bisphosphonates in osteoporosis. Osteoporos Int 1993;3:Suppl 2:S15-S22.
15. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bis-phosphonate (APD). Lancet 1988;1:143-6.
16. Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994;21:1922-6.
17. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
18. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
19. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337: 382-7.
20. Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998;83:1128-33.
21. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
22. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
23. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
24. Kiel D. Assessing vertebral fractures: National Osteoporosis Working Group on Vertebral Fractures. J Bone Miner Res 1995;10:518-23. [Erratum, J Bone Miner Res 1995;10:1605.]
25. Jergas M, San Valentin R. Techniques for the assessment of vertebral dimensions in quantitative morphometry. In: Genant HK, Jergas M, van Kuijk C, eds. Vertebral fracture in osteoporosis. San Francisco: Radiology Research and Education Foundation, 1995:163-88.
26. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 1996;11:984-96.
27. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985;41:295-301.
28. Capizzi T, Survill TT, Heyse JF, Malani H. An empirical and simulated comparison of some tests for detecting progressiveness of response with increasing doses of a compound. Biom J 1992;34:275-89.
29. Garnero P, Delmas PD. Assessment of serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
30. Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone 1995;16:499-503.
31. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
32. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
33. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.